Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
Fiche publication
Date publication
mai 2017
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The relationship of 5-aminosalicylates' use with the risk of colorectal neoplasia in patients with inflammatory bowel disease (IBD) has been the focus of a growing body of research.
Mots clés
Anti-Inflammatory Agents, Non-Steroidal, therapeutic use, Colitis, Ulcerative, drug therapy, Colorectal Neoplasms, prevention & control, Crohn Disease, drug therapy, Humans, Mesalamine, therapeutic use, Risk
Référence
Aliment. Pharmacol. Ther.. 2017 05;45(9):1179-1192